IPCALAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member IPCALAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member IPCALAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member IPCALAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2019-04-01 2020-03-31 2020-06-05 INR Crores Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Audited Standalone 10047900000.00 133000000.00 10180900000.00 3710600000.00 508500000.00 -949700000.00 2278800000.00 34700000.00 453800000.00 2572500000.00 8609200000.00 1571700000.00 0.00 1571700000.00 281800000.00 12300000.00 294100000.00 0.00 1277600000.00 0.00 0.00 0.00 0.00 1277600000.00 -33300000.00 1244300000.00 0.00 0.00 252700000.00 2 10.11 10.10 0.00 0.00 10.11 10.10 0.00 0.00 0.00 The above audited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on June 16, 2020. n nThe Company’s Resolution Plan under the Insolvency and Bankruptcy Code, 2016 for Noble Explochem Ltd. (NEL) was approved by the National Company Law Tribunal (NCLT) vide its order dated January 22, 2020. Pursuant thereto, the Company has discharged its total obligation and has acquired control over NEL’s vast land bank and infrastructure facility near Nagpur. As per the Resolution Plan, on approval by the NCLT, NEL merged with the Company with effect from the Completion Date without obtaining any separate order from NCLT. As per the aforesaid plan NEL’s entire capital gets cancelled. The Company has recognised immovable properties, plant and machineries and other assets acquired at its respective fair value in terms of Ind AS 16 on Property, Plant and Equipment based on valuation reports of authorized valuers appointed by the Resolution Professionals. The Company proposes to use these assets to set up manufacturing unit(s) for manufacturing of Drug Intermediates and Active Pharmaceutical Ingredients. n nBeing manufacturers of pharmaceuticals, the operations of the Company were exempted from lockdown declared by both the Central and State Governments in the wake of Covid - 19 pandemic. The Company continued with the manufacturing operations at all its manufacturing sites albeit with challenges such as shortage of manpower, availability of materials and disruptions in the logistics and supply chain. The Company has considered the possible effects that may result due to the lockdown announced consequent to outbreak of Covid -19 on the carrying amounts of property, plant and equipment, investments, inventories, receivables and other current assets. Based on internal and external sources of information and economic forecasts, the Company expects the carrying amount of these assets will be recovered and will continue to have sufficient liquidity to fund its business operations as well as expansion plans. However, a definitive assessment of the impact, at this stage, is not possible in view of the highly uncertain economic environment and the situation is still evolving. n n*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review. n nThe Company has only one reportable primary business segment viz. 'Pharmaceuticals'. n nFigures for the previous period have been regrouped / re-classified to conform to the figures of the current period. Single segment 2019-04-01 2020-03-31 Audited Standalone 43674300000.00 646900000.00 44321200000.00 14311000000.00 2046500000.00 -1550500000.00 8707900000.00 157900000.00 1786900000.00 11011800000.00 36471500000.00 7849700000.00 0.00 7849700000.00 1379800000.00 -54700000.00 1325100000.00 0.00 6524600000.00 0.00 0.00 0.00 0.00 6524600000.00 -76700000.00 6447900000.00 0.00 0.00 252700000.00 2 36522700000.00 51.64 51.60 0.00 0.00 51.64 51.60 0.00 0.00 0.00 Other Expenses 2572500000.00 Other Expenses 11011800000.00